- Drugs
- Saturday, 20 Jun 2020
Glenmark Becomes the First Pharmaceutical Company in India to Receive Regulatory Approval for Oral Antiviral Favipiravir, for the Treatment of Mild to Moderate COVID-19
In a landmark development for COVID-19 patients in India, Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced the launch of antiviral drug Favipiravir (brand name FabiFlu®) for the treatment of mild to moderate COVID-19 patients. Glenmark has received manufacturing and marketing approval from India's drug regulator, making FabiFlu® the first oral Favipiravir-approved medication in India for the treatment of COVID-19.
Commenting on the significance of this development, Mr. Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals Ltd., said, "This approval comes at a time when cases in India are spiralling like never before, putting a tremendous pressure on our healthcare system. We hope the availability of an effective treatment such as FabiFlu® will considerably help assuage this pressure, and offer patients in India a much needed and timely therapy option."
Glenmark successfully developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu® through its own in-house R&D team. Most patients exhibiting mild to moderate symptoms can benefit from FabiFlu® use. The drug will be available as a prescription-based medication, with recommended dose being 1800 mg twice daily on day 1, followed by 800 mg twice daily up to day 14.
Related Industry Updates
Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient
Jun 29, 2020
Europe Small Molecule Drug Delivery Market Opportunity Assessment and Forecast up to 2027
Sep 05, 2020
AstraZeneca ties up with IQVIA to speed up studies of COVID-19 vaccine candidate
Jul 15, 2020
MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry
Jun 27, 2020
Infectious Disease Therapeutics Market is expected to reach US$ 1,67,883.93 million by 2030
Jan 25, 2024
COVID-19 Fallout Drives Major Increases for Driven's Online Cannabis Sales
Mar 17, 2020
Tocotrienol Market Estimated to Expand at a Robust CAGR over 2020-2027
Mar 15, 2021